Literature DB >> 29592993

Systemic inflammatory response in a liver transplant recipient: a potential side effect of mycophenolate mofetil.

Rebecca Smith1, Adam Testro1,2.   

Abstract

Mycophenolate mofetil is a commonly used immunosuppressive medication in the postliver transplant setting where gastrointestinal side effects tend to predominate. However, in more recent times, emerging and rare side effects are being reported in the literature. We present a case of a patient who had a significant inflammatory response and associated marked weight loss with the uptitration in dose of mycophenolate mofetil. Extensive investigations were performed to exclude other infective, inflammatory or malignant aetiologies for these symptoms, however no other cause was identified. The patient had the medication ceased and subsequently had a dramatic improvement in his inflammatory markers and regained the weight lost while on the medication. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  gastrointestinal system; transplantation

Mesh:

Substances:

Year:  2018        PMID: 29592993      PMCID: PMC5878301          DOI: 10.1136/bcr-2017-223767

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Drug fever caused by mycophenolate mofetil in a renal transplant recipient--a case report.

Authors:  S C Chueh; J C Hong; C Y Huang; M K Lai
Journal:  Transplant Proc       Date:  2000-11       Impact factor: 1.066

2.  Pneumonitis associated with the use of mycophenolate mofetil.

Authors:  Nabin K Shrestha; Sherif B Mossad; William Braun
Journal:  Transplantation       Date:  2003-05-27       Impact factor: 4.939

Review 3.  Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management.

Authors:  M Behrend
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.

Authors:  Russell H Wiesner; Jolene S Shorr; Bettina J Steffen; Alice H Chu; Robert D Gordon; John R Lake
Journal:  Liver Transpl       Date:  2005-07       Impact factor: 5.799

5.  Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study.

Authors:  K Boudjema; C Camus; F Saliba; Y Calmus; E Salamé; G Pageaux; C Ducerf; C Duvoux; C Mouchel; A Renault; P Compagnon; R Lorho; E Bellissant
Journal:  Am J Transplant       Date:  2011-04-05       Impact factor: 8.086

6.  Mycophenolate mofetil induced myopathy in a patient with lupus nephritis.

Authors:  María Galindo; Ana Cabello; Beatriz Joven; Ana Alonso; Patricia Carreira; Jesús Porta; José Ramón Ricoy; Isabel Mateo; José L Pablos
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

Review 7.  Mycophenolate mofetil: a unique immunosuppressive agent.

Authors:  K A Hood; D G Zarembski
Journal:  Am J Health Syst Pharm       Date:  1997-02-01       Impact factor: 2.637

Review 8.  Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature.

Authors:  Marlene T Anderka; Angela E Lin; Dianne N Abuelo; Allen A Mitchell; Sonja A Rasmussen
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

9.  Changing treatment protocol from azathioprine to mycophenolate mofetil: decrease in renal dysfunction, increase in infections.

Authors:  V Pourfarziani; Y Panahi; S Assari; M Moghani-Lankarani; S-H Saadat
Journal:  Transplant Proc       Date:  2007-05       Impact factor: 1.066

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.